Tempus AI Faces Reimbursement Headwinds as CRUSH RFI Looms Over Strong Diagnostic Growth
Needham Virtual Healthcare Conference, April 14, 2026
Tempus AI is navigating an increasingly complex reimbursement landscape as federal cost-cutting initiatives threaten to reshape payment dynamics for diagnostic testing, even as the company posted robust 29% volume growth in oncology during the fourth quarter and secured major data partnership wins including a new strategic collaboration with Merck.
The company's stock was pressured last week alongside diagnostic peers following announcements around the CRUSH RFI initiative from the Centers for Medicare & Medicaid Services aimed at eliminating wasteful spending. CFO Jim Rogers acknowledged the evolving reimbursement environment but maintained that Tempus has built multiple hedging strategies, including operating labs in different MAC jurisdictions and pursuing FDA approvals to secure coverage under national coverage determinations.
Reimbursement Uncertainty Clouds Otherwise Strong Fundamentals
Rogers emphasized that "the reimbursement landscape has constantly evolved since we've started sequencing patients," but the company's multi-pronged mitigation approach should position it well to adapt. Still, the timing and magnitude of potential changes remain uncertain, creating near-term visibility challenges for a business that had been gaining momentum on the pricing front.
The reimbursement concerns come at an inopportune time for Tempus, which had been making steady progress on its ASP expansion initiative. The company previously outlined a path to increase average selling prices by over $500 through three initiatives: migrating tests to the FDA-approved XT-CDx version (worth approximately $200), securing approval and ADLT status for its liquid biopsy test xF, and improving commercial payer contracts (worth over $100).
Rogers reported that between 30% and 40% of volume had been migrated to the ADLT version of XT-CDx by year-end 2025, with confidence that "the vast majority" of remaining volume will transition during 2026. The xF liquid biopsy test was submitted to the FDA earlier this year, though it won't impact 2026 rates, with the benefit expected to materialize in 2027 upon approval.
Oncology Growth Accelerates on Sales Force Productivity Gains
Despite reimbursement uncertainties, Tempus is gaining market share in oncology testing. The 29% volume growth in Q4 represented an acceleration from earlier periods, driven by sales force realignment efforts initiated in the prior year. Rogers noted that by Q2 2025, "we had started to kind of see efficiency kind of tick up in the sales force, and that continued over the balance of the year."
The oncology market itself continues to expand, with Rogers estimating that approximately 55% of cancer patients now receive genomic sequencing, up from the company's previous estimate of one-third. This leaves substantial room for continued market expansion, though Tempus is clearly outgrowing the broader market through share gains driven by its differentiated insights and comprehensive test portfolio spanning DNA, RNA, liquid, solid, and germline testing.
The company positions itself as a one-stop shop for oncologists, offering tumor-informed and tumor-naive minimal residual disease testing through its partnership with Personalis alongside internally developed offerings. This breadth of portfolio increasingly matters as attach rates for AI algorithm add-ons have reached 40% of orders, demonstrating physician appreciation for the additional clinical context Tempus provides.
Hereditary Growth Moderating After Exceptional 2025
The hereditary testing business, largely comprising the legacy Ambry acquisition from 2025, is experiencing a normalization in growth rates after an exceptional year driven by competitor disruption. Rogers acknowledged that hereditary growth "began to moderate in Q4 and will continue to moderate in Q1," though the rare disease diagnosis segment within hereditary represents an untapped opportunity with stronger growth potential given recent reimbursement approvals.
The hereditary segment operates in a more mature market than therapy selection, with limited ASP expansion opportunities except as the higher-reimbursed rare disease testing becomes a larger mix component. Rogers noted that Ambry has operated "largely independently" during the first year of ownership, with ongoing evaluation of how to incorporate its data into Tempus' life sciences partnerships expected to continue through 2026 and into 2027.
Data Business Momentum Building with Major Partnership Wins
The data and services segment is demonstrating accelerating momentum, with total contract value climbing to over $1.1 billion from $940 million, including $350 million attributed to 2026 revenue. This backlog provides substantial visibility given the segment generated $370 million in 2025 revenue.
Tempus announced a new strategic collaboration with Merck alongside an expansion with Gilead early in 2026, representing the evolution of relationships Rogers described as typically developing over multiple years. "These are folks that we have been working with previously on a smaller scale. They've obviously seen the value that our data can bring to their drug discovery efforts and have decided to expand kind of those relationships more broadly across kind of multiple indications," he explained.
The company now works with 19 of the top 20 pharmaceutical companies and several hundred biotechs, though many remain in the "small or mid-tier in terms of the number of cohorts that they're licensing." This creates a "tremendous opportunity for us to march all of them up to kind of the strategic collaborations" that will fuel multi-year growth.
Importantly, Rogers clarified that even large strategic collaborations don't provide unlimited access to Tempus' data. Partners licensing data commit to higher spending levels to secure volume discounts, but "it doesn't mean that you can download all of the records." Only "a relatively small percentage of the overall database" is accessible under these agreements, preserving significant expansion potential even within existing strategic relationships.
AstraZeneca Foundation Model Progressing on Schedule
The pathology foundation model collaboration with AstraZeneca, announced in spring 2025, has progressed as expected, with Tempus delivering the first version to AstraZeneca. Rogers noted that "development and training of that model has gone well," though he cautioned that replicating such large deals is difficult to predict given their scale.
The company is seeing increased interest in smaller, indication-specific models, with ongoing discussions around such opportunities. While Tempus retains rights to leverage the model to enhance its own diagnostics and data products, Rogers indicated those benefits won't materialize from the first version. "You start to identify some of these insights that we can either turn into enhancements or insights in our diagnostics or leveraging the model to improve the effectiveness of our data products, that work is ongoing," he said.
AI Applications Await Reimbursement Framework
The AI applications portfolio, including FDA-approved algorithms in cardiology and radiology alongside the DigiPath offering from the Paige acquisition, continues to scale clinically but lacks a robust reimbursement framework. Rogers acknowledged "there isn't kind of a great answer on kind of timing of when that changes" but expressed confidence that "it would be very odd for us that the health care system wouldn't want to pay for things that can have a positive ROI on kind of overall spend."
The company's strategy involves deploying algorithms to build clinical evidence while simultaneously lobbying for reimbursement policy changes. These applications leverage existing hospital integrations, allowing for rapid scaling once reimbursement materializes. However, Rogers confirmed AI applications are "not something that we're building in" to 2026 guidance and won't have "a significant impact in '27" either.
Both private payers and government programs recognize the potential value but require proof before committing to payment. "Show me how exactly this plays out in reality such that we see the value that we think we're going to see," Rogers characterized the typical payer conversation.
Investment Framework Balances Growth and Profitability
Tempus maintains its framework of reinvesting two-thirds of incremental gross profit dollars back into growth initiatives while allowing one-third to flow through to adjusted EBITDA, assuming 25% annual growth. This approach is expected to continue for approximately three years before reversing to reinvesting only one-third as gross profit dollars scale sufficiently.
Rogers emphasized the company takes a measured approach to new initiatives, starting "very small to medium" when entering new disease areas before doubling down on what works. On the M&A front, Tempus views its diagnostics portfolio as "pretty well-rounded" following the Ambry acquisition, with future deals more likely to be "smaller tuck-in acquisitions" focused on complementary technologies or capabilities.
The company evaluates all M&A through the lens of improving patient care and ensuring deals don't divert from continued business leverage. With Ambry representing an outsized acquisition relative to historical patterns, investors should expect a return to smaller, technology-focused deals that enhance existing platforms rather than transformative portfolio additions.
Tempus AI Deep Dive
The Multi-Modal Data Thesis
The core value proposition of Tempus AI rests upon the assumption that the future of oncology and precision medicine lies not merely in molecular sequencing, but in the intelligent integration of multi-modal data. By creating a proprietary library that marries clinical longitudinal records with molecular data at scale, the firm aims to fundamentally shorten the drug development cycle and refine clinical decision-making. This approach addresses the historic fragmentation of healthcare data, where clinical outcomes and genomic findings have resided in disparate silos. Tempus seeks to function as the operating system for the next generation of data-driven medicine, attempting to create a network effect where each additional clinical case processed improves the predictive accuracy of the AI models, which in turn attracts more clinicians and pharmaceutical partners.
However, the skepticism surrounding this model is rooted in the difficulty of data normalization. While the company claims superior data quality, the reality of healthcare interoperability means that much of the clinical input remains noisy, inconsistent, and highly dependent on the quality of the originating electronic health record systems. The transition from diagnostic test provider to data-driven pharmaceutical partner requires a level of institutional trust that remains a significant hurdle. Tempus must prove that its algorithmic insights are not merely descriptive of past outcomes but possess the prescriptive power to alter clinical trajectories or reduce the R&D burn rate for major biopharmaceutical clients significantly.
Industry Structure and Competitive Moats
The precision medicine diagnostic and data analytics market is characterized by high barriers to entry regarding laboratory accreditation and clinical evidence, but it suffers from extreme commoditization in testing. While many firms provide molecular profiling, the true differentiator for Tempus is the platform, not the test. The structural challenge is that the diagnostic business is a low-margin, high-volume endeavor that requires constant capital reinvestment to maintain pace with evolving genomic standards. The defensive moat relies on the cumulative size of the proprietary database. If the database reaches a critical mass where it can reliably predict drug response rates across specific genetic subsets better than public data repositories, the competitive advantage becomes formidable.
Yet, this moat is not unassailable. The industry has seen a clear bifurcation between companies that provide static data reports and those attempting to build active learning systems. Tempus is firmly in the latter category, but it faces a structural threat from the rapid advancement of open-source genomic tools and the decreasing cost of data storage and processing. If the fundamental genomic insights become easily replicable through commodity software, the value shifts entirely to the proprietary clinical dataset. The durability of the Tempus advantage, therefore, hinges on its ability to maintain exclusive access to high-quality, real-world evidence that its competitors cannot easily replicate through partnership or purchase.
The Limits of Data Liquidity
A persistent concern in the evaluation of Tempus involves the liquidity and transferability of the clinical data it manages. While the company touts its ability to organize and structure health records, regulatory scrutiny regarding patient privacy, data sovereignty, and the monetization of protected health information is intensifying globally. Any pivot in regulatory posture—such as more stringent HIPAA interpretations or new legislation governing the use of AI in medical diagnostics—could fundamentally impair the company's ability to extract value from its data warehouse. The business is structurally leveraged to a regulatory environment that permits the aggregation and commercialization of patient data, creating a hidden, non-operational risk that is difficult to hedge.
Furthermore, there is a persistent skepticism regarding the "AI" component of the company's branding. In an institutional context, the distinction between advanced statistical modeling and generative AI is critical. While Tempus utilizes machine learning to correlate multi-modal datasets, the reliance on high-quality human-curated data remains high. As long as the platform requires significant human oversight to interpret and standardize incoming patient files, the scalability of the model remains constrained. The transition to fully automated, high-fidelity data processing is the pivot point on which the company's long-term margin expansion rests.
New Opportunities in Biopharma Partnerships
The most credible pathway for meaningful revenue expansion lies in the deepening of biopharma partnerships. By embedding its platform directly into the clinical trial workflow, Tempus can move from a third-party vendor to an integral part of the drug development infrastructure. If the platform can reliably identify patient cohorts for orphan drug trials or predict the failure of specific compounds before they reach expensive Phase 3 trials, the firm could move toward a risk-sharing or milestone-based revenue model. This would represent a departure from the transactional diagnostic business and would fundamentally re-rate the quality of the company's earnings.
This expansion strategy is not without execution risk. Partnering with major pharmaceutical firms requires long lead times, intense validation periods, and a high degree of integration risk. The current appetite among large pharmaceutical conglomerates for such deep technical dependency is uncertain. While major players are desperate to accelerate R&D timelines, they are notoriously cautious regarding the integration of external software platforms into their core development pipelines, often preferring proprietary, in-house solutions or established, lower-risk CROs.
The Competitive Landscape
The competitive environment is saturated with firms targeting the same oncology segment. Companies such as Caris Life Sciences and Guardant Health represent direct competitive threats that have already established deep penetration in the diagnostic market. Guardant, in particular, has demonstrated robust execution in liquid biopsy and minimal residual disease testing, effectively capturing a significant share of the market for serial monitoring of cancer patients. These incumbents possess established commercial infrastructure and deep relationships with oncologists that Tempus must displace.
While Tempus differentiates through its multi-modal data integration, the market is rapidly converging. Caris Life Sciences has significantly bolstered its own capabilities in molecular profiling and clinical data correlation, directly challenging the Tempus thesis on data-driven precision. These competitors are not standing still; they are all racing toward the same destination of becoming a comprehensive data and diagnostic hub. The risk is that the market may eventually split into smaller, entrenched geographic or hospital-system networks, preventing any single firm from achieving the dominant scale required to make the AI models truly predictive. In this scenario, the industry would face prolonged, margin-diluting price competition rather than the winner-take-all outcome implied by the bull case.
Management Execution and Capital Efficiency
Management, led by Eric Lefkofsky, has demonstrated a significant aptitude for capital raising and public narrative control. The company’s ability to frame itself as an AI-native company has historically garnered it premium valuation multiples compared to its pure-play diagnostic peers. However, the legacy of prior ventures and the aggressive nature of the firm’s growth strategy demand a disciplined assessment of capital allocation. The operational burn rate remains high, reflecting the costs associated with the physical infrastructure of labs and the ongoing high-cost human-in-the-loop requirement for data curation.
The primary concern for institutional observers is the potential for management to pursue growth at the expense of margin discipline. The firm must prove that it can transition from its current high-growth, high-burn phase to a state of self-sustaining capital efficiency. A pattern of consistent, incremental improvement in gross margins, driven by the automation of data curation and the scaling of the pharmaceutical partnership pipeline, will be the true test of management's operational maturity. If the firm remains reliant on external capital to fund its growth for an extended period, it risks significant dilution and potential strategic drift if the market environment for growth-oriented healthcare stocks tightens.
The Scorecard
The assessment of Tempus AI reveals a company caught between the transformative potential of its multi-modal data thesis and the brutal realities of the diagnostic industry. The firm’s ability to organize longitudinal patient data is undeniably significant, providing a potential edge in clinical research and drug discovery that pure-play diagnostic labs lack. However, this advantage is being aggressively challenged by well-funded competitors who are similarly pivoting toward data-driven insights. The company’s reliance on complex, human-intensive data curation processes creates a structural drag on margin expansion, and the long-term dependency on a favorable regulatory environment for data monetization introduces an external risk factor that cannot be fully mitigated by operational excellence.
Ultimately, the investment thesis rests on whether the firm can successfully transition from being a diagnostic provider that uses data to a pharmaceutical-adjacent technology firm that earns recurring, high-margin revenue from partnerships. While the intellectual foundation is sound, the execution path is narrow and fraught with competition from both established incumbents and potential disruptors. The current valuation reflects high expectations for this transition, and any failure to demonstrate consistent progress toward profitability will likely result in a significant recalibration of investor sentiment. The company sits at a critical juncture where the narrative must be substantiated by clinical evidence and sustained commercial success in the biopharma sector.